<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560583</url>
  </required_header>
  <id_info>
    <org_study_id>BRZ 0046-17 CTIL</org_study_id>
    <nct_id>NCT03560583</nct_id>
  </id_info>
  <brief_title>Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients</brief_title>
  <official_title>Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barzilai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barzilai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poor ovarian response population of ART are considered the biggest challenge for providers.
      Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.

      Metoclopramide belongs to the antiemetic group, used for motion sickness and during early
      gestation for hyperemesis gravidarum.

      The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking
      dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase
      the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation
      and result in increased oocyte retrival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes</measure>
    <time_frame>Approximately 5 weeks from first dose of study drug</time_frame>
    <description>Number of oocytes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Poor Responders in IVF</condition>
  <arm_group>
    <arm_group_label>Metoclopramide 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 10 mg BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>Metoclopramide 10 mg BID</description>
    <arm_group_label>Metoclopramide 10 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo 10 mg BID</description>
    <arm_group_label>Placebo 10 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor response according to &quot;Bologna criteria&quot;

        Exclusion Criteria:

          -  Allergy to metoclopramide

          -  Prolactinemia

          -  Women treated with dopamine agonists
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Grin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barzilai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leon Grin, MD</last_name>
    <phone>972-50-5999379</phone>
    <email>leonti.grin@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2018 Sep;31(18):2492-2505. doi: 10.1080/14767058.2017.1342805. Epub 2017 Jul 11. Review.</citation>
    <PMID>28614956</PMID>
  </reference>
  <reference>
    <citation>Hernández I, Parra A, Méndez I, Cabrera V, Cravioto MC, Mercado M, Díaz-Sánchez V, Larrea F. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome. Arch Med Res. 2000 Mar-Apr;31(2):216-22.</citation>
    <PMID>10880731</PMID>
  </reference>
  <reference>
    <citation>Prelević GM, Würzburger MI, Perić LA. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome. J Endocrinol Invest. 1988 Apr;11(4):255-9.</citation>
    <PMID>3137253</PMID>
  </reference>
  <reference>
    <citation>Mendes MC, Ferriani RA, Sala MM, Moura MD, Carrara HH, de Sá MF. Effect of transitory hyperprolactinemia on in vitro fertilization of human oocytes. J Reprod Med. 2001 May;46(5):444-50.</citation>
    <PMID>11396370</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barzilai Medical Center</investigator_affiliation>
    <investigator_full_name>Leon Grin</investigator_full_name>
    <investigator_title>Gynecological Doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

